Baxter establishes $200M VC fund
This article was originally published in Clinica
Executive Summary
Baxter International has become the latest healthcare multinational to establish its own venture capital fund. The company has announced plans to create Baxter Ventures to invest up to $200m in promising early-stage companies developing therapies that complement Baxter's existing portfolio. With many traditional venture capital houses moving away from early-stage drug discovery and development investing, an increasing number of pharmaceutical companies are creating their own corporate venture arms to fill the innovation investment vacuum.